

M U N I
M E D


Pathophysiology of blood clotting disorders

VLA 16.4.2020


Hemostasis

- The normal physiological response that prevents significant blood loss following vascular injury is called haemostasis.⁶ Familiarity with haemostasis lays the groundwork for a thorough understanding of the major disease states associated with thrombosis, such as venous thromboembolism (VTE), atherothrombosis (thrombosis triggered by plaque rupture), and cardioembolic stroke.

Hemostasis



CLOT FORMATION




Abnormal haemostasis

- Excessive coagulation leads to the formation of a thrombus, potentially obstructing blood flow. This is a common problem, especially in hospitalised or immobilised patients. Venous thromboembolic disease, for example, is a major problem in the European Union, where it causes more than one million events or deaths every year.
Excessive bleeding results when certain coagulation factors are lacking, as in patients with haemophilia.


Blood vessel injury

- Blood vessel injury triggers the following sequence:
 - The vessel constricts to reduce blood flow
 - Circulating platelets adhere to the vessel wall at the site of trauma
 - Platelet activation and aggregation, coupled with an intricate series of enzymatic reactions involving coagulation proteins, produces fibrin to form a stable haemostatic plug
- This finely tuned process serves to maintain the integrity of the circulatory system. However, the process can go out of balance, leading to significant morbidity and mortality.

Platelet Activation Pathways (1)




Platelet Activation Pathways (2)




The coagulation cascade

- Coagulation involves a complex set of protease reactions involving roughly 30 different proteins.
- The final result of these reactions is to convert fibrinogen, a soluble protein, to insoluble strands of fibrin. Together with platelets, the fibrin strands form a stable blood clot.



Site	Thrombogenic	Antithrombogenic
Vessel wall	Exposed endothelium	Heparin
	TF	Thrombomodulin
	Collagen	Tissue plasminogen activator
Circulating elements	Platelets	Antithrombin
	Platelet activating factor	Protein C and S
	Clotting factor	Plasminogen
	Prothrombin	
	Fibrinogen	
	vWF	

vWF – Von Willebrand factor; TF – Tissue factor



„Cell-based model“





- This model identifies membranes of cell presenting tissue factor (TF) and a surface of platelets as places of activation of specific coagulation factors.
- The model supposes the model of three phases: initiation, amplification (propagation) and the proper action of thrombin- thrombus formation.
- **Initiation** = formation of complex TF-FVIIa which is leading to activation of a small amount of thrombin.
- **Propagation** = activation of platelets by thrombin and formation of complex FIXa-FVIIIa with subsequent activation of factor Xa.
- **Thrombus formation** = formation of prothrombinase complex and of large amount of thrombin which is leading to formation of thrombus.

Coagulation Cascade

Text size [A](#) [A](#) [A](#)

- Coagulation Cascade
- Initiation Phase
- Propagation Phase
- Clot Formation
- Anticoagulation Drugs
- Natural Inhibitors
- Fibrinolysis

Legend:

-  = inactive factor
-  = active factor
-  = transformation
-  = catalysis


INITIATION



- Membrane-bound tissue factor (TF) activates Factor VII to Factor VIIa, leading to formation of the TF-VIIa complex.
- Membrane-bound TF-VIIa activates both Factor IX and Factor X.
- Factor Xa converts small amounts of prothrombin (Factor II) to thrombin (Factor IIa), which then activates Factor V and Factor VIII.

Iniciation phase of coagulation

Figure 2




Current concept of coagulation (initiation phase)

Initiation phase of coagulation

- Coagulation cascade is activated when defect of vessel wall enables contact of the blood with cells with TF.
- Platelets membrane bound tissue factor TF activates **FVII to VIIa** which is leading to formation of complex **TF-VIIa**.
- The complex binding on platelets membranes activates **Factor IX(a) and Factor X(a)**.
- **Factor Xa** converts small amount of prothrombin (Faktor II) on trombin (**Factor IIa**) which can activate Factor V on **FVa** and Factor VIII on **FVIIIa**.

Propagation phase of coagulation



Current concepts of coagulation (propagation phase)


Propagation of coagulation: central role for Factor Xa

- **Factor Xa** together with activated Factor V (Va) as cofactor support coagulation by thrombin formation (Factor IIa) from prothrombin (Factor II).
- **Factor Xa** is primary point for propagation of the process; one molecule of **Factor Xa** catalyses formation of about 1,000 molecules of **thrombin**.

Final step: fibrin formation


- In the final step, sequence of serin proteinases reactions which lead to formation of blood clot, **thrombin** will convert soluble fibrinogen to insoluble **fibrin**.
- **Thrombin** also activates **Factor XIII** (stabilizing fibrin) which can stabilize clot by crosslinking of fibrin.
- Stabilized fibrin is able to retain cellular components (red blood cells, platelets or both).


(a) Conversion of plasminogen to plasmin



(b) Plasmin α_2 -antiplasmin complex

Fibrinolýza





Regulation of the fibrinolytic system

Articles from Indian Journal of Anaesthesia are provided here courtesy of Medknow Publications





Natural inhibitors of coagulation

- „Tissue factor plasminogen inhibitor“ –produced by endothelial cells. It inhibits complex TF-VIIa.
- Antithrombin (previously AT III) – binds activated vitamin K dependent coagulation factors (can be activated by heparin which increases its binding capacity)
- „Protein Z dependent protease inhibitor/ protein Z (PZI)“ produced by liver. It inhibits FXa in presence PZ and Ca⁺⁺.

Coagulation Cascade

- Coagulation Cascade
- Anticoagulation Drugs
- Natural Inhibitors
- Fibrinolysis

Legend:


-  = inactive factor
-  = active factor
-  = transformation
-  = catalysis

TFPI
Tissue factor pathway inhibitor (TFPI) from endothelial and other cells forms a complex with Factor Xa to inactivate it. The TFPI-Xa complex then inactivates the membrane-bound TF-VIIa complex.

APC
Activated protein C (APC) inactivates Factors Va and VIIIa with protein S as a cofactor. APC is converted from protein C by a complex of thrombin and thrombomodulin. Thrombomodulin is bound to the membranes of endothelial cells.

AT
Antithrombin (AT) binds activated coagulant Factors (IIa, IXa, Xa, XIa and XIIa) that are not clot-bound or in the prothrombinase complex. AT is activated by endothelial heparan sulfate.

NATURAL INHIBITORS




Text size A A **A**

Antithrombin (AT) is a serine protease inhibitor (SERPIN) that inhibits factors XIa, IXa, Xa, FVIIa/TF, and Thrombin (IIa)

AT inhibitory activity is increased 1000 fold by heparin

Plasma half-life is 60-70 hours

Antithrombin (and Heparin)



Protein C

- Classification
 - Type I (quantitative)
 - Type II (qualitative)
- Relative risk for thrombosis ~6.5
- Onset of thrombosis is before middle age (<45 years)
- Homozygous deficiency is associated with neonatal purpura fulminans

Relative risk is ratio of the cumulative incidence rate in the exposed to the cumulative incidence rate in the non-exposed population

Protein S

- PS either circulates freely as Free PS (40%) or bound to C4b-Binding Protein (60%)
 - Free form is active
 - C4b-BP is acute phase reactant
- Relative risk for thrombosis ~2 but difficult to predict since in some families the risk is substantial (possible interaction with other defects)

Type	PS Activity	Free PS Antigen	Total PS Antigen
I	Low	Low	Low
II	Low	Normal	Normal
III	Low	Low	Normal

Acquired Deficiencies: PC, PS, AT

- Acquired deficiencies of Protein C and Protein S
 - Oral anticoagulants (warfarin) or Vitamin K deficiency
 - Liver disease
 - Post-operatively
 - Disseminated Intravascular Coagulation (DIC)
 - Consumption during an acute thrombotic event
 - PS also reduced in nephrotic syndrome and pregnancy
- Acquired deficiencies of Antithrombin
 - Heparin therapy
 - L-asparaginase therapy
 - Liver disease
 - Nephrotic syndrome

Coagulation factors -state


- **Non activated**-after their synthesis in liver
- **Posttranslationally modified** –vitamin K dependent coagulation factors = serin proteázy
- **Activated** –activated serin proteases, other activated factors (Va, VIIIa)

Role of Liver in Hemostasis


- Site for synthesis
 - All coagulation factors (except VWF)
 - Regulators of coagulation proteins (Antithrombin, Protein C, Protein S)
 - Fibrinolytic proteins (Plasminogen, Antiplasmin, Thrombin Activatable Fibrinolysis Inhibitor [TAFI])
- Site for carboxylation of vitamin K-dependent proteins
 - Procoagulant factors: II, VII, IX, X and anticoagulant proteins: Protein C, Protein S
 - Process allows these proteins to bind to cellular membranes and participate in macromolecular complex formation on these surfaces resulting in Thrombin formation
- Site for clearance
 - Activated coagulation factors, enzyme-inhibitor complexes (ie, thrombin-antithrombin complexes), & fibrin degradation products

Synthesis of Vitamin K-Dependent Coagulation Factors


Vitamin K absorption and metabolism



Vitamin K mechanism of action



Synthesis of functional forms of VII, IX, X and II depends on vitamin K, the cofactor for a carboxylase enzyme that adds γ-carboxyl groups to glutamic acids in nascent coagulation proteins VII, IX, X and II



TESTS

✘ Screening tests

✘ Bleeding time

✘ Platelet count

✘ Prothombin time (PT)

✘ Partial thromboplastin time (PTT)

✘ Thrombin time (TT)

✘ More specific tests

Sampling

- Venous blood
- Excessive stress and exercise cause changes in blood clotting. and fibrinolysis.
- Whenever possible, venous samples should be collected without a pressure cuff (to avoid haemoconcentration, increase of fibrinolysis, platelet release, and activation of some clotting factors.
- To minimize the effect of contact activation plastic or polypropylene, siliconized glass, syringes and containers should be used.
- Thoroughly mixing the blood with the anticoagulant by inverting the containers several time.
- The sample should be brought to the laboratory as soon as possible.
- Labeling the patient sample is very important.

Sampling

- ✘ Anticoagulant trisodium citrate 3.2 % in a ratio of 1 : 9.
- ✘ Time of sample collection is very important factor in the interpretation of results.
- ✘ Centrifugation and preparation of platelets poor plasma - 4000 rpm in a cooling centrifuge.
 - + P.T & Factor VII → kept at room temperature.
 - + Other assays → at 4°C.
- + Testing should preferably be completed within 2 hours of the collection.

BLEEDING TIME

✘ **Time** taken for bleeding to cease from a small superficial wound

✘ **Affected by**

- Platelet count and function
- Vessel wall

- **Normal range** Ivy's method: 2-7 **min**

PLATELET COUNT

- ✘ Normal platelet count = $150-400 \times 10^9/L$
- ✘ A part of complete blood picture (CBC)
- ✘ Performed by electronic counters or manually (inherent error)

PROTHROMBIN TIME

- ✘ Indicates the overall efficiency of **ex**trinsic pathway of blood coagulation (**FVII**, FII, FV, X)

- ✘ Normal range: 10-14 **sec**

PROTHROMBIN TIME

✘ Causes of prolonged PT

- Liver disease
- Vit K deficiency (FII, V, VII, IX are Vit k dependent)
- Deficiency of factors involved in extrinsic pathway
- DIC
- Oral anticoagulants

PARTIAL THROMBOPLASTIN

✘ Indicates the overall efficiency of **in**trinsic pathway of blood coagulation (**FVIII**, **FIX**, FXI, FXII, FII, FV, X)

✘ Normal range: 30-40 **sec**

PARTIAL THROMBOPLASTIN

✘ Causes of prolonged PTT

- Deficiency of factors involved in intrinsic pathway (coagulation factors other than FVII)
- Liver disease
- DIC
- Massive transfusion (labile FV, FVIII)
- Heparin

PT & PTT

✘ Prolonged PT + normal PTT = **ex**trinsic pathway defect

✘ Prolonged PTT + normal PT = **in**trinsic pathway defect

✘ Prolonged PT and PTT = **common** pathway defect or **combined**
factor deficiencies

THROMBOCYTOPENIA

✘ Platelet count below $150 \times 10^9/L$

✘ Causes:

✘ - Congenital

- Acquired

- failure of production

✘ Increased destruction (*ITP*)

✘ - Splenic sequestration (*hypersplenism*)

Idiopathic Thrombocytopenic Purpura

× **ITP** is immune thrombocytopenia due to formation of **antibodies** against platelets and BM megakaryocytes.

× **Clinical picture**: spontaneous bleeding purpuric eruptions.

× **BT**: **prolonged**

× **Platelet count**: **thrombocytopenia**

× **PT, PTT**: normal

× **BM**: **increased megakaryocytes** with poor platelet separation

QUALITATIVE PLATELET DEFECT

✘ Platelet function defect + normal plt count

✘ Causes:

- Hereditary (Glanzmann's disease, Bernard-Soulier syndrome)
- Acquired (drugs as *aspirin*, uremia)

QUALITATIVE PLATELET DEFECT

- ✘ **Clinical picture:** spontaneous bleeding purpuric eruptions.
- ✘ **BT:** prolonged
- ✘ **Platelet count:** normal or slightly decreased
- ✘ **PT, PTT, TT:** normal
- ✘ **Platelet function:** abnormal depending on the defect (defective aggregation in Glanzmann's disease and Bernard-Soulier syndrome)


Hereditary Thrombophilia

- Hereditary thrombophilia
- AT deficiency
- Protein C deficiency
- Protein S deficiency
- Factor V Leiden
- Prothrombin polymorphism (G/A 20210 in 3' area of the gene)

Acquired Thrombotic disorders

- Sy of antiphospholipid antibodies
- Increased levels of factors VIII, IX, XI and fibrinogen
- Fibrinolysis defects

- Tendency to develop thrombi in veins (venous thrombosis) or arteries (arterial thrombosis)
 - Thrombophilia in western countries is frequently used in the context of venous thrombosis
- Thrombosis is a complex (multicausal) disease in which many different pathways can contribute to the risk of developing disease
 - Singularly, inherited and acquired risk factors have may have only a moderate effect
 - Risk is greatly increased when two or more risk factors combine
 - Genetic and genetic
 - Genetic and environmental



- Risk factors for thrombosis - Disorders
 - Antiphospholipid Syndrome (APS)
 - Underlying malignancy
 - Pregnancy/postpartum
 - Heparin-Induced Thrombocytopenia (HIT)
 - Paroxysmal Nocturnal Hemoglobinuria (PNH)
 - Disseminated Intravascular Coagulation (DIC)
- Risk factors for thrombosis - Environmental
 - Stasis due to prolonged immobilization, obesity
 - High risk surgeries (orthopedic)
 - Trauma
 - Previous thrombosis
 - Oral contraception (OC) and hormone replacement therapy (HRT)

Heparin/LMWH—Adverse Effects

– Heparin

- Bleeding
- Thrombocytopenia
- Osteoporosis
- Hypersensitivity

■ LMWH

- Bleeding
- Thrombocytopenia
- Hypersensitivity


Warfarin—Adverse Effects

- Fatal or non-fatal hemorrhage from any tissue or organ
- Necrosis of skin and other tissues
- Other adverse reactions reported less frequently include:
 - Systemic cholesterol microembolization
 - Alopecia
 - Purple toes syndrome, urticaria, dermatitis including bullous eruptions

Venous Thrombosis

- Venous system: low flow & pressure
- Thrombi are fibrin rich
- Function of age, biologic conditions, genetic & environmental factors, and their interactions
- Venous thromboembolism (VTE)
 - Deep vein thrombosis (DVT)
 - Pulmonary embolism (PE)
 - Superficial, portal, cerebral, or retinal vein thrombosis
- Reasons for coagulation testing
 - Risk for recurrence of thrombosis
 - Treatment considerations (duration & intensity)
 - Genetic counseling for affected family members
 - Prophylaxis for high risk situations

Prevalence for Venous Thrombosis



- FV Leiden 20%
- Surgery/Trauma 16%
- FVIII (>150U/ml) 16%
- Immobilization 15%
- Malignancy 10-15%
- APS 2-14%
- HyperHyc 5-10%
- PT 20210 6%
- Protein C 3%
- Protein S 1%
- Antithrombin 1%
- Dysfibrinogenemia <1%

HyperHyc: Hyperhomocysteinemia


- Decreased activity of natural anticoagulants
 - Antithrombin, Protein C, and Protein S
 - Penetrance is incomplete and expression is dependent upon presence of second genetic defect and environmental factors
- Impaired downregulation of procoagulant activity
 - Activated Protein C Resistance (Factor V Leiden)
- Increased procoagulant activity of plasma proteins
 - Fibrinogen, Prothrombin (PT 20210), factors VIII, IX, XI
- Impaired fibrinolysis (weak association)
 - Plasminogen (deficiency), FXIII polymorphisms

Protein C (PC) and Protein S (PS) are Vitamin K-dependent natural anticoagulants

Thrombin in the presence of Thrombomodulin (TM) “modulates” its own procoagulant activities to those of anticoagulant by activating PC, in the presence of its cofactor PS, to Activated PC (APC)

APC downregulates coagulation cofactors, VIIIa and Va


Protein C and Protein S



A single base mutation (guanine to adenine at position 1691 of the *FV gene*) is responsible for the Arg506Gln mutation known as FV Leiden

Phenotype is characterized by a reduced anticoagulant response to APC (FV Leiden is inactivated 10 fold slower than normal FV)

Activated Protein C Resistance (APCR) Factor V Leiden




Polymorphism (adenine substituted for guanine at nucleotide 20210) in the 3'-untranslated region of the gene encoding for Factor II (Prothrombin)

Patients heterozygous for the mutation have elevated levels of Prothrombin but activity levels can not be used to exclude genetic defect

Prothrombin 20210

Factor II Levels and Thrombosis



Poort et al. Blood 1996;88:3698-3703

- Risk factors for thrombosis - Disorders
 - Antiphospholipid Syndrome (APS)
 - Underlying malignancy
 - Pregnancy/postpartum
 - Heparin-Induced Thrombocytopenia (HIT)
 - Paroxysmal Nocturnal Hemoglobinuria (PNH)
 - Disseminated Intravascular Coagulation (DIC)
- Risk factors for thrombosis - Environmental
 - Stasis due to prolonged immobilization, obesity
 - High risk surgeries (orthopedic)
 - Trauma
 - Previous thrombosis
 - Oral contraception (OC) and hormone replacement therapy (HRT)

Venous Thrombosis

- Venous system: low flow & pressure
- Thrombi are fibrin rich
- Function of age, biologic conditions, genetic & environmental factors, and their interactions
- Venous thromboembolism (VTE)
 - Deep vein thrombosis (DVT)
 - Pulmonary embolism (PE)
 - Superficial, portal, cerebral, or retinal vein thrombosis
- Reasons for coagulation testing
 - Risk for recurrence of thrombosis
 - Treatment considerations (duration & intensity)
 - Genetic counseling for affected family members
 - Prophylaxis for high risk situations

Thrombosis and AF

- AF is the most common arrhythmia seen in clinical practice.
- Without appropriate anticoagulant treatment, most patients with AF are at increased risk of cardioembolic stroke.

Thrombosis and coronary artery disease

- Cardiovascular disease is the leading cause of death in industrialised countries. **Coronary artery disease** (CAD) is the most common form of cardiovascular disease. In CAD, atherosclerosis damages the coronary artery wall, predisposing to thrombus formation. The symptoms and severity of acute coronary syndromes (unstable **angina** and myocardial infarction) vary depending on the degree to which thrombi occlude the coronary arteries.

VASCULAR DISORDERS

✘ Pattern of bleeding: purpura

✘ Causes.....

- Screening tests for hemostasis:
- BT: **prolonged**
- Platelet count: normal
- - PT, PTT, TT: normal

Table 8.22

Vascular disorders

Congenital

Hereditary haemorrhagic telangiectasia
(Osler-Weber-Rendu disease)

Connective tissue disorders (Ehlers-Danlos syndrome, osteogenesis
imperfecta, pseudoxanthoma elasticum, Marfan's syndrome)

Acquired

Severe infections:

Septicaemia

Meningococcal infections

Measles

Typhoid

Allergic

Henoch-Schönlein purpura

Autoimmune disorders (SLE, rheumatoid arthritis)

Drugs

Steroids

Sulphonamides

Others

Senile purpura

Easy bruising syndrome

Scurvy


Factitious purpura

Table 8.24
Causes of thrombocytopenia

Impaired production	Excessive destruction
<p>Bone marrow failure Megaloblastic anaemia Leukaemia Myeloma Myelofibrosis Solid tumour infiltration Aplastic anaemia drugs chemicals viruses paroxysmal nocturnal haemoglobinuria</p>	<p>Immune AITP Secondary immune (SLE, CLL, viruses, drugs, e.g. heparin) Alloimmune neonatal thrombocytopenia Post-transfusion purpura</p> <p>Sequestration Hypersplenism</p> <p>Dilutional Massive transfusion</p> <p>Other Disseminated intravascular coagulation Thrombotic thrombocytopenic purpura Haemolytic uraemic syndrome</p>

BLEEDING DISORDERS

✘ Abnormal bleeding may result from

- Vascular disorders
- Thrombocytopenia (↓ platelet count )
- Defective platelet function (qualitative defect)
- Coagulation disorders

Hereditary Bleeding diseases

- Von Willebrand's disease
- Hemophilia A
- Hemophilia B
- Hemophilia C
- Factor V deficiency
- Factor VII deficiency
- Factor XIII deficiency
- Prothrombin deficiency

Acquired bleeding disorders

- Consumption coagulopathies
- DIC-disseminated intravascular coagulation
- Microangiopathic hemolytic anemia
- Vitamin K deficiency
- Liver diseases

Hemophilia A and B

- Inheritance is X-linked
- Severity of bleeding depends on levels of FVIII or FIX
 - Mild: activity levels between 5-25%
 - Have significant bleeding after major trauma or surgery but generally go undetected until abnormal APTT is found
 - Moderate: activity levels between 2-5%
 - Bleeding is precipitated by trauma or surgery
 - Severe: less than 1% activity
 - Present with recurrent hemorrhages that occur spontaneously or after minor trauma/surgery
- Clinical presentation
 - 90% of bleeding episodes occur into the joints (knees and elbows predominantly)
 - Intramuscular, intracranial, & gastrointestinal




www.macmed.ttuhscc.edu

The Defect in Hemophilias

Hemophilia A (FVIII), Hemophilia B (FIX), and Hemophilia C (FXI) are disorders of the Propagation Phase of coagulation


Thrombin is initially generated via the TF/FVIIa Initiation Phase however, the large amounts of Thrombin necessary for adequate secondary hemostasis are not generated



✗ = Defect

Hemophilia A

- ✘ X-linked disorder
- ✘ Quantitative or qualitative disorder of factor VIII
- ✘ Screening tests:
 - ✘ BT: normal
 - ✘ Platelet count: normal
 - ✘ PT: normal
 - ✘ PTT: prolonged
 - ✘ Platelet count: normal
- ✘ Specific test: FVIII assay: decreased activity



(a) Factor VIII synthesis.

(b) Hemofilia A has a defect synthesis of VIIIc.

(c) von Willebrand's disease has a reduced synthesis of vWF

Hemophilia B


✘ Also called Christmas disease

✘ Compared to hemophilia A:

- Less common
- same presentation
- Same screening tests results
- Specific test: **FIX assay**: decreased activity

Von Willebrand Factor Roles

Primary Hemostasis
(Adhesion step)



Secondary Hemostasis
(Amplification and Propagation phases)

Adapted from: Monroe DM, et al. ATVB 2006;26:41-8

Von Willebrand Disease (VWD)

- Most common bleeding disorder in humans
- Autosomal inheritance
- ~ 0.8 - 1.3% of population has a detectable, inherited defect in Von Willebrand Factor (VWF)
 - Low VWF levels, bleeding, and family history (the “holy” three)
- Types of bleeding
 - Mucocutaneous bleeding
 - Epistaxis, menorrhagia, ecchymoses & hematomas, gingival and gastrointestinal bleeding
 - Results from defect in primary hemostasis
 - Soft tissue bleeding (after trauma/injury)
 - Dental extraction, wounds, post-operatively, post-partum
 - Results from defect in secondary hemostasis
 - VWF is carrier (protector) protein for FVIII

Von Willebrand Disease

- Autosomal dominant disease
- Quantitative or qualitative disorder of vWF
- Von Willebrand factor acts as a carrier for FVIII
- Acts as an essential cofactor for platelet adhesion and aggregation

Von Willebrand Disease

✘ Screening tests:

- ✘ BT : **prolonged.**
- ✘ Platelet count: normal
- ✘ PT: normal
- ✘ PTT: **prolonged**

✘ Specific tests:

- ✘ **Platelet aggregation**: defective with ristocetin
- ✘ **FVIII assay**: decreased activity
- ✘ **vWF antigen** : reduced



Acquired Causes for Bleeding

- Liver Disease
- Immune coagulopathies
 - Inhibitors have been described to each of the coagulation factors
- Disseminated intravascular coagulation (DIC)
- Pharmacologic overdosing
- Primary fibrinogenolysis
 - Plasmin acts on fibrinogen
- Acquired platelet defects due to
 - Uremia, myeloproliferative disorders, antiplatelet antibodies, drugs that inhibit platelet function (administered in excess)

DIC (disseminated intravascular coagulation)

- ✘ Release of **tissue factor, TF**.
- ✘ TF is expressed on many cell types (endothelial, macrophages, monocytes).
- ✘ Contact with blood after damage of vessel wall (the effects of cytokines and endotoxins).
- ✘ TF is binding to coagulation factors which is leading to activation of both pathways of coagulation cascades.
- ✘

Disseminated intravascular coagulation (DIC)

- ✘ Due to extensive **coagulation** followed by **fibrinolysis** with consumption of hemostatic factors.

- ✘ Causes:
 - ✘ infection, malignancy, obstetric complications, liver disease

Diagnosis of DIC

- × BT: prolonged
- × Platelet count: decreased
- × PT: prolonged
- × PTT: prolonged
- × TT: prolonged
- × Fibrinogen level: reduced
- × FDPs (D dimer): increased
- × Red cell fragmentation in the blood film

	BT	PT	PTT	Platelet count	Platelet function	Other tests
ITP	P	N	N	↓		
Glanzman	P	N	N	N	Defect aggreg	
Hemoph A	N	N	P	N		FVIII assay
Hemoph B	N	N	P	N		FIX assay
vWD	P	N	P	N	Defect aggreg	FVIII, vWF
DIC	P	P	P	↓		Fibrinogen FDPs

Thank you for your attention



M U N I

M E D